Opthea Limited (ASX:OPT)
A clinical-stage healthcare player Opthea Limited is engaged in developing treatments for ophthalmic diseases. The Company has exclusive rights for significant worldwide intellectual property (IP) portfolio around VEGF-C, VEGF-D and VEGFR-3. The IP of Opthea is held within Vegenics Pty Ltd wholly-owned subsidiary of the Company.
Opthea to host Key Opinion Leader Symposium on Wet AMD & DME
On 28 July 2020, Opthea revealed that the Company would host a KOL symposium with a live Q&A for shareholders, investors & analysts focused on OPT-302. OPT-302 is Opthea’s first-in-class biologic inhibitor of VEGF-C/D, development for the treatment of wet AMD and DME (diabetic macular edema).
ALSO READ: Healthcare Corner: Lens on CSL and Opthea
The Company notified that the event would be held on 6 August 2020 at 9:00 AM AEST.
Opthea Presented New Data from Phase 1b/2a DME Trial at ASRS
On 27 July 2020, Opthea disclosed that new data from the Phase 1b/2a clinical trial of OPT-302 in DME had been presented at the 2020 Annual Meeting of the American Society of Retina Specialists (ASRS).
The Company reported favourable visual function as well as anatomical outcomes after OPT-302 combination therapy in patients having diabetic macular edema with continual disease despite previous treatment with the SoC anti-VEGF-A therapy.
Moreover, Opthea notified that the Phase 2a DME trial is in progress with additional analyses & the results for long-term safety and treatment durability to be completed in the H2 CY2020.
Addition to the undergoing Phase 2a trial, the Company continues to start planning for its Phase 3 trial in wet AMD, together with regulatory engagement in Europe and the US. The Company is also planning to progress manufacturing of OPT-302 for Phase 3 clinical trials.
CEO and Managing Director, Opthea Limited Dr Megan Baldwin commented-
- Forums
- ASX - By Stock
- OPT
- Ann: Opthea to Host Key Opinion Leader Symposium on wAMD and DME
Ann: Opthea to Host Key Opinion Leader Symposium on wAMD and DME, page-2
Featured News
Add OPT (ASX) to my watchlist
(20min delay)
|
|||||
Last
74.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $490.4M |
Open | High | Low | Value | Volume |
76.0¢ | 78.8¢ | 74.0¢ | $1.401M | 1.867M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 4995 | 74.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
75.5¢ | 4996 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 4995 | 0.740 |
1 | 4996 | 0.735 |
1 | 4996 | 0.730 |
2 | 15996 | 0.725 |
3 | 65881 | 0.720 |
Price($) | Vol. | No. |
---|---|---|
0.755 | 4996 | 1 |
0.760 | 4996 | 1 |
0.765 | 4996 | 1 |
0.770 | 4996 | 1 |
0.775 | 34973 | 1 |
Last trade - 16.10pm 28/03/2024 (20 minute delay) ? |
|
|||||
Last
75.0¢ |
  |
Change
0.000 ( 0.07 %) |
|||
Open | High | Low | Volume | ||
76.0¢ | 78.5¢ | 74.5¢ | 235028 | ||
Last updated 15.59pm 28/03/2024 ? |
Featured News
OPT (ASX) Chart |
The Watchlist
BGD
BARTON GOLD HOLDINGS LIMITED
Alex Scanlon, Managing Director & CEO
Alex Scanlon
Managing Director & CEO
SPONSORED BY The Market Online